Estrella Immunopharma, Inc. (NASDAQ:ESLAW) Sees Large Increase in Short Interest

Estrella Immunopharma, Inc. (NASDAQ:ESLAW) was the target of a significant increase in short interest during the month of December. As of December 15th, there was short interest totaling 5,904 shares, an increase of 66.7% from the November 30th total of 3,541 shares. Based on an average daily volume of 19,899 shares, the short-interest ratio is presently 0.3 days. Based on an average daily volume of 19,899 shares, the short-interest ratio is presently 0.3 days.

Estrella Immunopharma Trading Down 2.0%

ESLAW stock traded down $0.00 during trading on Tuesday, hitting $0.05. The company had a trading volume of 44,000 shares, compared to its average volume of 15,306. Estrella Immunopharma has a 52-week low of $0.03 and a 52-week high of $0.24. The company has a 50 day simple moving average of $0.10 and a 200-day simple moving average of $0.07.

Estrella Immunopharma Company Profile

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103.